Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy
Status:
Terminated
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
This study will seek to enroll 50 persons who have central or non-central geographic atrophy
(GA) associated with age-related macular degeneration (AMD). GA in treated eye must be
between 0.75 disk areas (DA) and 8 DA. Eligible participants will be randomly chosen to
receive one of the following treatments in the study eye:
1. A 20 μL (440 μg) intravitreal (IVT) injection of sirolimus, or
2. A sham treatment (subconjunctival injection of lidocaine) Participants with two (2)
eligible eyes will have one eye randomly assigned to receive intravitreal sirolimus and
no sham in the fellow eye.
The first injection will begin at Day 0, which may occur on the date of screening/enrollment
or up to two weeks following screening/enrollment visit, and every month thereafter. The
visit schedule is as follows:
1. A clinical evaluation, including safety measures, will occur monthly.
2. Vision will be measured at the screening/enrollment visit and at 2, 3, 6, 9, 12, 18 and
24 months after the first injection has occurred.
3. Fundus autofluorescence will occur at screening/enrollment and at 2, 6, 12, 18 and 24
months after the first injection has occurred.
4. Fundus color photography and optical coherence tomography will occur at
screening/enrollment and at 6, 12, 18 and 24 months after the first injection has
occurred.
The primary goal is to evaluate whether the persons receiving the sirolimus injections show a
slower worsening of geographic atrophy compared to the persons receiving the sham injections.
A secondary goal is to evaluate the impact of sirolimus on vision compared to the sham.
NOTE: As of May 30, 2014, study injections were discontinued due to safety concerns. No
further enrollments will occur and follow-up will continue on all active study participants
on a quarterly basis. That is, on visits coinciding with 3 month intervals from date of
enrollment.
Phase:
Phase 2
Details
Lead Sponsor:
National Eye Institute (NEI)
Collaborators:
Santen Inc. The Emmes Company, LLC The EMMES Corporation